Article
Biochemistry & Molecular Biology
Shuang Yu, Changan Liu, Yingtong Hou, Jie Li, Zhuming Guo, Xinwen Chen, Luyao Zhang, Sui Peng, Shubin Hong, Lixia Xu, Xiaoxing Li, Rengyun Liu, Shuwei Chen, Bin Li, Zongpeng Weng, Yanbing Li, Weiming Lv, Jun Yu, Haipeng Xiao
Summary: Discriminating papillary thyroid cancer (PTC) from benign thyroid nodule (BTN) is challenging, but this study identified a panel of 17 differential metabolites that can effectively differentiate between the two. The panel showed high sensitivity and specificity in both discovery and validation cohorts, and it also improved the accuracy and specificity for diagnosing papillary thyroid microcarcinoma compared to ultrasound.
Article
Multidisciplinary Sciences
Sarita Devi, Roshni M. Pasanna, Nikhil Nadiger, Santu Ghosh, Anura V. Kurpad, Arpita Mukhopadhyay
Summary: The study found that the duration of tourniquet application significantly affects the variability in plasma metabolite concentrations, recommending minimizing tourniquet application time and waiting for 5 minutes after removal to reduce variability and false interpretations.
SCIENTIFIC REPORTS
(2021)
Article
Biochemistry & Molecular Biology
Biao Qi, Yanyu Zhang, Bing Xu, Yuhao Zhang, Guoqiang Fei, Ling Lin, Qiuping Li
Summary: Acute ischemic stroke is a condition where one of the brain's main arteries is suddenly blocked, leading to insufficient oxygen and nutrients for brain cells. In this study, the metabolic changes in the biofluids of AIS patients were analyzed, revealing 29 significantly altered metabolites. The results showed a clear distinction between AIS patients and healthy controls, providing a sensitive and feasible diagnostic prospect for AIS patients.
APPLIED BIOCHEMISTRY AND BIOTECHNOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Sona Rivas-Tumanyan, Lorena S. Pacheco, Danielle E. Haslam, Liming Liang, Katherine L. Tucker, Kaumudi J. Joshipura, Shilpa N. Bhupathiraju
Summary: This study assessed the longitudinal associations between plasma metabolites, their network-derived clusters, and the progression of type 2 diabetes (T2D) in Puerto Rican adults. The findings highlight potential prognostic biomarkers for identifying high-risk individuals and suggest the need for further research on the role of diet and lifestyle in modifying these associations.
Article
Pharmacology & Pharmacy
Yuqing Meng, Jiayun Chen, Yanqing Liu, Yongping Zhu, Yin-Kwan Wong, Haining Lyu, Qiaoli Shi, Fei Xia, Liwei Gu, Xinwei Zhang, Peng Gao, Huan Tang, Qiuyan Guo, Chong Qiu, Chengchao Xu, Xiao He, Junzhe Zhang, Jigang Wang
Summary: The composition of serum is highly complex, making the discovery of new pharmacodynamic biomarkers challenging. This study developed a nanoparticle-based proteomic analysis strategy to enhance the range of serum proteomic analysis. The strategy successfully identified more proteins and enriched biological processes, providing potential pharmacodynamic biomarkers for disease prediction, diagnosis, and treatment.
JOURNAL OF PHARMACEUTICAL ANALYSIS
(2022)
Article
Food Science & Technology
Linyuan Shen, Jianfeng Ma, Haodi Zhou, Lei Chen, Jie Tang, Kaige Zhang, Ye Zhao, Lili Niu, Shunhua Zhang, Anan Jiang, Jinyong Wang, Zongyi Guo, Xuewei Li, Yiwu Chen, Mailin Gan, Li Zhu
Summary: This study aimed to identify biomarkers for pork quality evaluation. The pH of pork meat was found to be negatively correlated with meat color indicators, and differential metabolites were enriched in amino acid and energy metabolism pathways. Correlation analysis revealed potential plasma biomarkers for predicting pork quality based on pH value.
Article
Oncology
Lars Guelen, Thierry O. Fischmann, Jerelyn Wong, Smita Mauze, Marco Guadagnoli, Nikolina Babala, Jozef Wagenaars, Veronica Juan, David Rosen, Winnie Prosise, Maurice Habraken, Imke Lodewijks, Danling Gu, Judith Stammen-Vogelzangs, Ying Yu, Jeanne Baker, David Lutje Hulsik, Lilian Driessen-Engels, Dan Malashock, Joost Kreijtz, Astrid Bertens, Evert de Vries, Astrid Bovens, Arne Bramer, Yiwei Zhang, Richard Wnek, Sean Troth, Elliot Chartash, Konstantin Dobrenkov, Svetlana Sadekova, Andrea van Elsas, Jason K. Cheung, Laurence Fayadat-Dilman, Jannie Borst, Amy M. Beebe, Hans Van Eenennaam
Summary: MK-5890, a novel CD27 agonistic antibody, has the potential to complement PD-1 checkpoint inhibition in cancer immunotherapy and is currently undergoing clinical evaluation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Xiedong Hong, Lang Tian, Qiong Wu, Liming Gu, Wenli Wang, Hanxu Wu, Mingxiao Zhao, Xiaojin Wu, Chang Wang
Summary: In this study, plasma metabolic characteristics in hematopoietic stem cell transplantation patients undergoing total body ionizing irradiation were investigated using gas chromatography-mass spectrometry and liquid chromatography-mass spectrometry. High dose radiation caused metabolic disorders involving dysregulation of gut microflora, shift in energy supply, and protein synthesis and metabolism. Four metabolic markers (PC-O-38:5, urate, ornithine, and GCDCS) were chosen as potential biomarkers for radiation injury. Specific metabolic changes were found in specific patients following high doses of exposure. These findings provide valuable information for selecting metabolic biomarker panels and understanding radiation pathology.
Article
Medicine, General & Internal
Estefania Nunez, Valentin Fuster, Maria Gomez-Serrano, Jose Manuel Valdivielso, Juan Miguel Fernandez-Alvira, Diego Martinez-Lopez, Jose Manuel Rodriguez, Elena Bonzon-Kulichenko, Enrique Calvo, Alvaro Alfayate, Marcelino Bermudez-Lopez, Joan Carles Escola-Gil, Leticia Fernandez-Friera, Isabel Cerro-Pardo, Jose Maria Mendiguren, Fatima Sanchez-Cabo, Javier Sanz, Jose Maria Ordovas, Luis Miguel Blanco-Colio, Jose Manuel Garcia-Ruiz, Borja Ibanez, Enrique Lara-Pezzi, Antonio Fernandez-Ortiz, Jose Luis Martin-Ventura, Jesus Vazquez
Summary: This study identified circulating proteins that are associated with subclinical atherosclerosis and can predict the disease. These proteins offer potential for improving primary prevention strategies in areas where cardiovascular imaging is not available.
Article
Biochemistry & Molecular Biology
Ana Filipa Fernandes, Luis Gafeira Goncalves, Maria Bento, Sandra Anjo, Bruno Manadas, Clara Barroso, Miguel Villar, Rita Macedo, Maria Joao Simoes, Ana Varela Coelho
Summary: This study aimed to discover molecular biomarkers for the early diagnosis of tuberculosis. Proteomics and metabolomics analyses were performed, and a combination of protein and metabolite markers was found to accurately identify tuberculosis patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Nutrition & Dietetics
Meriah S. Schoen, Rani H. Singh
Summary: This study used untargeted metabolomics to identify significant disruptions in amino acid and lipid metabolites in females with phenylketonuria (PKU), which were associated with bioenergetic impairment and oxidative stress. Choline-conjugated lipids were found to play a fundamental role in these pathways, and had not been previously evaluated in PKU. Short-term intervention at a metabolic camp effectively improved or normalized the abundance of the identified metabolites.
AMERICAN JOURNAL OF CLINICAL NUTRITION
(2022)
Article
Oncology
Amy T. Ku, Adelaide I. J. Young, Ahmed Atef Ibrahim, Wen Bu, Weiyu Jiang, Meng Lin, Laterrica C. Williams, Bryant Lee McCue, George Miles, Chandandeep Nagi, Fariba Behbod, Yi Li
Summary: Antiestrogen medication is the only current chemoprevention for high-risk women, but it takes years to work and has side effects. Therefore, developing a short-course, effective chemoprevention strategy is important. PIK3CA is commonly activated in breast atypical hyperplasia, a known precursor to breast cancer. Targeting PI3K signaling in these precancerous lesions may offer a new strategy for chemoprevention.
CANCER PREVENTION RESEARCH
(2023)
Article
Geriatrics & Gerontology
Di Liu, Lijuan Zhao, Yu Jiang, Liya Li, Muyao Guo, Yibing Mu, Honglin Zhu
Summary: In this study, plasma and urine samples from newly diagnosed IIM patients were analyzed using untargeted metabolomics. The results showed that IIM subtypes have specific metabolic signatures and pathways in both plasma and urine. This study provides valuable insights for understanding the molecular mechanisms, identifying potential diagnosis biomarkers, and finding therapeutic targets for IIM.
JOURNAL OF CACHEXIA SARCOPENIA AND MUSCLE
(2022)
Review
Chemistry, Multidisciplinary
Stephane Perreault, Jayaraman Chandrasekhar, Leena Patel
Summary: Atropisomerism is a type of axial chirality that results in non-superimposable stereoisomers due to hindered rotation. Considering the rotational energy barrier and interconversion rate between atropisomers is important in drug discovery. The introduction of sigma bond with restricted rotation in bioactive molecules can limit the number of accessible conformations and improve their pharmacokinetics/ADME profiles. Recent advances in synthesis, purification, and analysis have enabled the application of atropisomerism in medicinal chemistry.
ACCOUNTS OF CHEMICAL RESEARCH
(2022)
Article
Medicine, General & Internal
Celine Occelli, Jean-Marie Guigonis, Sabine Lindenthal, Alexandre Cagnard, Fanny Graslin, Vesna Brglez, Barbara Seitz-Polski, Jean Dellamonica, Jacques Levraut, Thierry Pourcher
Summary: Our study demonstrated that plasma metabolome profiling is an efficient tool for the diagnosis and prognosis of SARS-CoV-2 infection. We successfully distinguished healthy controls, mild SARS-CoV-2 subjects, and moderate and severe COVID-19 patients using plasma metabolome fingerprinting. The study revealed the impact of SARS-CoV-2 infection on the plasma metabolome, particularly in mild cases, and identified important biomarkers for infection detection and severity assessment.
FRONTIERS IN MEDICINE
(2022)
Review
Oncology
D. Araujo, A. Greystoke, S. Bates, A. Bayle, E. Calvo, L. Castelo-Branco, J. de Bono, A. Drilon, E. Garralda, P. Ivy, O. Kholmanskikh, I. Melero, G. Pentheroudakis, J. Petrie, R. Plummer, S. Ponce, S. Postel-Vinay, L. Siu, A. Spreafico, A. Stathis, N. Steeghs, C. Yap, T. A. Yap, M. Ratain, L. Seymour
Summary: In 2021, the FDA Oncology Center of Excellence launched Project Optimus to optimize dosage for oncology drugs. The MDICT Taskforce reviewed and discussed dosage optimization for oncology trials, providing recommendations for trial design and a practical guide for phase I trials. The aim is to improve dosage selection in early clinical trials of new anticancer treatments and ultimately enhance patient outcomes.
ANNALS OF ONCOLOGY
(2023)
Article
Oncology
Kim N. Chi, Alan Barnicle, Caroline Sibilla, Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann de Bono, Joaquin Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington
Summary: This study evaluated the utility of plasma-derived circulating tumor DNA (ctDNA) in identifying BRCA1, BRCA2, and ATM alterations in patients with metastatic castration-resistant prostate cancer. The results showed that ctDNA detection can complement tissue testing and serve as a valuable alternative for patients with no or insufficient tissue for genomic analyses.
CLINICAL CANCER RESEARCH
(2023)
Article
Oncology
Nobuaki Matsubara, Johann de Bono, David Olmos, Giuseppe Procopio, Satoru Kawakami, Yuksel Urun, Robbert van Alphen, Aude Flechon, Michael A. Carducci, Young Deuk Choi, Sebastien J. Hotte, Ernesto Korbenfeld, Gero Kramer, Neeraj Agarwal, Kim N. Chi, Simon Dearden, Christopher Gresty, Jinyu Kang, Christian Poehlein, Elizabeth A. Harrington, Maha Hussain
Summary: The purpose of this study was to evaluate the use of ctDNA testing as an alternative method to identify mCRPC patients with HRR gene alterations who may benefit from olaparib treatment. The results showed that ctDNA testing can be a suitable alternative when tissue testing is not feasible or has failed.
CLINICAL CANCER RESEARCH
(2023)
Article
Urology & Nephrology
Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhofer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono
Summary: This study evaluated the efficacy and safety of pembrolizumab plus olaparib in previously treated patients with metastatic castration-resistant prostate cancer. The results demonstrated antitumor activity and expected safety of this combination therapy in patients.
Article
Urology & Nephrology
Silke Gillessen, Alberto Bossi, Ian D. Davis, Johann de Bono, Karim Fizazi, Nicholas D. James, Nicolas Mottet, Neal Shore, Eric Small, Mathew Smith, Christopher Sweeney, Bertrand Tombal, Emmanuel S. Antonarakis, Ana M. Aparicio, Andrew J. Armstrong, Gerhardt Attard, Tomasz M. Beer, Himisha Beltran, Anders Bjartell, Pierre Blanchard, Alberto Briganti, Rob G. Bristow, Muhammad Bulbul, Orazio Caffo, Daniel Castellano, Elena Castro, Heather H. Cheng, Kim N. Chi, Simon Chowdhury, Caroline S. Clarke, Noel Clarke, Gedske Daugaard, Maria De, Ignacio Duran, Ros Eeles, Eleni Efstathiou, Jason Efstathiou, Onyeanunam Ngozi Ekeke, Christopher P. Evans, Stefano Fanti, Felix Y. Feng, Valerie Fonteyne, Nicola Fossati, Mark Frydenberg, Vvww Daniel, Martin Gleave, Gwenaelle Gravis, Susan Halabi, Daniel Heinrich, Ken Herrmann, Celestia Higano, Michael S. Hofmanfff, Lisa G. Horvath, Maha Hussain, Barbara Alicja Jereczek-Fossakkk, Robert Jonesmmm, Ravindran Kanesvaran, Pirkko-Liisa Kellokumpu-Lehtinen, Raja B. Khauli, Laurence Klotz, Gero Kramer, Raya Leibowitz, Christopher J. Logothetisp, Brandon A. Mahal, Fernando Maluf, Joaquin Mateo, David Matheson, Niven Mehra, Axel Merseburger, Alicia K. Morgans, Michael J. Morris, Hind Mrabti, Deborah Mukherji, Declan G. Murphy, Vedang Murthy, Paul L. Nguyen, William K. Oh, Piet Ost, Joe M. O'Sullivan, Anwar R. Padhani, Carmel Pezaro, Darren M. C. Poon, Colin C. Pritchard, Danny M. Rabah, Dana Rathkopf, Robert E. Reiter, Mark A. Rubin, Charles J. Ryan, Fred Saad, Juan Pablo Sade, Oliver A. Sartor, Howard Scher, Nima Sharifi, Iwona Skoneczna, Howard Soule, Daniel E. Spratt, Sandy Srinivas, Cora N. Sternberg, Thomas Steuber, Hiroyoshi Suzuki, Matthew R. Sydes, Mary-Ellen Taplin, Derya Tilki, Levent Turkeri, Fabio Turco, Hrioji Uemura, Hirotsugu Uemura, Yuksel Urun, Claire L. Vale, Inge van Oort, Neha Vapiwala, Jochen Walz, Kosj Yamoah, Dingwei Ye, Evan Y. Yu, Almudena Zapatero, Thomas Zilli, Aurelius Omlin
Summary: The voting results from the 2022 Advanced Prostate Cancer Consensus Conference provide valuable insights for clinical management in areas where high-level evidence is lacking. These results can guide physicians and patients in making treatment decisions and help prioritize future research.
Editorial Material
Urology & Nephrology
Khobe Chandran, Rafael Grochot, Maria de Los Dolores Fenor De La Maza, Wei Yuan, Bora Gurel, Susana Miranda, Alec Paschalis, Ruth Riisnaes, Ines Figueiredo, Denisa Bogdan, Adam Sharp, Suzanne Carreira, Johann S. de Bono
Correction
Urology & Nephrology
Evan Y. Yu, Josep M. Piulats, Gwenaelle Gravis, Peter C. C. Fong, Tilman Todenhoefer, Brigitte Laguerre, Jose A. Arranz, Stephane Oudard, Christophe Massard, Julia Heinzelbecker, Luke T. Nordquist, Joan Carles, Michael P. Kolinsky, Marinela Augustin, Howard Gurney, Ali Tafreshi, Xin Tong Li, Ping Qiu, Christian H. Poehlein, Charles Schloss, Johann S. de Bono
Article
Oncology
Thomas Jaki, Abigail Burdon, Xijin Chen, Pavel Mozgunov, Haiyan Zheng, Richard Baird
Summary: The pharmaceutical industry is facing a decline in productivity, especially in the development of oncology drugs. Establishing the potential and optimal dosage of novel treatments is crucial for efficient development. Using novel statistical designs can improve efficiency in dose-finding and accelerate the development of promising interventions. This paper discusses strategies for early oncology development, highlights missed opportunities for improved efficiency, and explores future opportunities in this field.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Medicine, General & Internal
Aude Espinasse, Olga Solovyeva, Munyaradzi Dimairo, Christopher Weir, Thomas Jaki, Adrian Mander, Andrew Kightley, Jeffry Evans, Shing Lee, Alun Bedding, Sally Hopewell, Khadija Rantell, Rong Liu, An-Wen Chan, Johann De Bono, Christina Yap
Summary: The DEFINE study aims to improve the transparency, completeness, reproducibility, and interpretation of EPDF trial protocols (SPIRIT-DEFINE) and their reports (CONSORT-DEFINE). An extensive review of published trials and consultation with international experts will be conducted to refine the guidelines. The final version of the guidelines will be determined through a modified Delphi process and an international consensus meeting.
Article
Medicine, General & Internal
Olga Solovyeva, Munyaradzi Dimairo, Christopher J. Weir, Siew Wan Hee, Aude Espinasse, Moreno Ursino, Dhrusti Patel, Andrew Kightley, Sarah Hughes, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Shing Lee, Sally Hopewell, Khadija Rerhou Rantell, An-Wen Chan, Alun Bedding, Richard Stephens, Dawn Richards, Lesley Roberts, John Kirkpatrick, Johann de Bono, Christina Yap
Summary: This study aims to develop guidelines for early phase dose-finding trials through reviewing published trial reports and conducting a Delphi process. The SPIRIT-DEFINE and CONSORT-DEFINE guidelines were developed, and a lay summary toolkit was created through patient and public involvement.
Article
Oncology
Valentine M. Macaulay, Simon Lord, Syed Hussain, Jose Pablo Maroto, Robert Hugh Jones, Miguel Angel Climent, Natalie Cook, Chia-Chi Lin, Shian-Shiang Wang, Diletta Bianchini, Mark Bailey, Laura Schlieker, Thomas Bogenrieder, Johann de Bono
Summary: This study evaluated the combination therapy of xentuzumab and enzalutamide in patients with metastatic castrate-resistant prostate cancer. The results showed that the combination treatment had some efficacy in certain patients.
BRITISH JOURNAL OF CANCER
(2023)
Review
Biochemistry & Molecular Biology
Antonino Glaviano, Aaron S. C. Foo, Hiu Y. Lam, Kenneth C. H. Yap, William Jacot, Robert H. Jones, Huiyan Eng, Madhumathy G. Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H. Kulke, Richard D. Baird, Jyothi S. Prabhu, Daniela Carbone, Camilla Pecoraro, Daniel B. L. Teh, Gautam Sethi, Vincenzo Cavalieri, Kevin H. Lin, Nathalie R. Javidi-Sharifi, Eneda Toska, Matthew S. Davids, Jennifer R. Brown, Patrizia Diana, Justin Stebbing, David A. Fruman, Alan P. Kumar
Summary: The PI3K/AKT/mTOR (PAM) signaling pathway plays a crucial role in cell survival, growth, and cell cycle progression. Dysregulation of this pathway is associated with cancer development and resistance to therapy. This review focuses on the major dysregulations in the PAM signaling pathway in cancer and discusses strategies for overcoming treatment resistance. The role of PAM signaling in immunology and immunotherapies is also discussed.
Article
Multidisciplinary Sciences
R. Charles Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O'Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Summary: This study reports the clinical trial results of samuraciclib as an anti-cancer treatment, showing its clinical activity in patients with triple negative breast cancer and HR+/HER2- breast cancer.
NATURE COMMUNICATIONS
(2023)
Article
Medicine, General & Internal
Christina Yap, Olga Solovyeva, Johann de Bono, Jan Rekowski, Dhrusti Patel, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Sally Hopewell, Moreno Ursino, Khadija Rerhou Rantell, Melanie Calvert, Shing Lee, Andrew Kightley, Deborah Ashby, An-Wen Chan, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Munyaradzi Dimairo, Christopher J. Weir
Summary: The CONSORT-DEFINE guidance provides comprehensive reporting guidelines for early phase dose-finding trials, aiming to improve the quality of reporting and facilitate result interpretation.
BMJ-BRITISH MEDICAL JOURNAL
(2023)
Article
Medicine, General & Internal
Christina Yap, Jan Rekowski, Moreno Ursino, Olga Solovyeva, Dhrusti Patel, Munyaradzi Dimairo, Christopher J. Weir, An-Wen Chan, Thomas Jaki, Adrian Mander, Thomas R. Jeffry Evans, Richard Peck, Kathryn S. Hayward, Melanie Calvert, Khadija Rerhou Rantell, Shing Lee, Andrew Kightley, Sally Hopewell, Deborah Ashby, Elizabeth Garrett-Mayer, John Isaacs, Robert Golub, Olga Kholmanskikh, Dawn P. Richards, Oliver Boix, James Matcham, Lesley Seymour, S. Percy Ivy, Lynley Marshall, Antoine Hommais, Rong Liu, Yoshiya Tanaka, Jordan Berlin, Aude Espinasse, Johann de Bono
Summary: SPIRIT 2013 provides guidance for clinical trial protocol writing but doesn't cover early phase dose-finding trials adequately. The DEFINE statement is a new guideline that includes recommendations for essential items in the protocols of these trials.
BMJ-BRITISH MEDICAL JOURNAL
(2023)